AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise
Source: SeekingAlpha
2026-02-04 18:04:48 ET
The last time I spoke about AbbVie Inc. ( ABBV ) it was in a Seeking Alpha article entitled as " AbbVie: Increased Outlook For 2025 And Expansions Merit Continued 'Strong Buy' Rating ." For this article I had noted a Strong Buy rating on the stock, despite its drug HUMIRA continuing to see a decline. I also mentioned that it had robust growth in both of its immunology and neuroscience portfolios as well....
Read the full article on Seeking Alpha
For further details see:
AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise
AbbVie Inc.
NASDAQ: ABBV
ABBV Trading
-0.97% G/L:
$224.48 Last:
1,406,476 Volume:
$226.89 Open:
ABBV Latest News
March 13, 2026 01:36:56 pm
Concorde Financial Exits Howard Hughes Holdings, Developer of Large Sun Belt Communities
ABBV Stock Data
$396,361,630,803
1,749,710,786
N/A
2503
N/A
Pharmaceuticals
Healthcare
US
North Chicago
